Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: Results of a prospective randomised trial

Journal of Plastic Surgery and Hand Surgery

Volumn 44, Issue 3, 2010, Pages 146-155

  Bergenmar, Mia ^a   Mnsson Brahme, Eva ^a   Hansson, Johan ^a   Brandberg, Yvonne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Emotional distress; Health related quality of life; Malignant melanoma; Randomised trial; Surgical resection margins

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MELANOMA; MENTAL STRESS; METHODOLOGY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCAR; SKIN TUMOR; SURGERY; ETIOLOGY; PROCEDURES; SKIN NEOPLASMS;

CICATRIX; HUMANS; MELANOMA; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SKIN NEOPLASMS; STRESS, PSYCHOLOGICAL; SURGICAL PROCEDURES, OPERATIVE;

EID: 77953173908     PISSN: 2000656X     EISSN: 16512073     Source Type: Journal    
DOI: 10.3109/02844311003791136     Document Type: Article

References (17)

1. Lens MB, Nathan P, Bataille V. Excision margins for primary cutaneous melanoma - updated pooled analysis of randomized controlled trials. Arch Surg 2007;9:885-891
2. Balch C, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-267
3. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101-108
4. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757-766
5. Newton-Bishop J, Nolan C, Turner F, et al. A quality-of-life study in high-risk (thickness ‡ 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004;9:152-159
6. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85: 365-376
7. Fayers PM, Aronson NK, Bjordal K, Groenvold M, Curran D, Bottomly A on behalf of the EORTC Quality of life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.
8. Bergman B, Sullivan M, Sörenson S. Quality of life during chemotherapy for small cell lung cancer. I. An evaluation with generic health measures. Acta Oncol 1991;30:947-957
9. Sigurdardottir V, Brandberg Y, Sullivan M. Criterion-based validation of the EORTC QLQ C-36 in advanced melanoma: the CIPS questionnaire and proxy raters. Qual Life Res 1996;5:375-386
10. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370
11. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77.
12. Arving C, Glimelius B, Brandberg Y. Four weeks of daily assessments of anxiety, depression and activity compared to a point assessment with the Hospital Anxiety and Depression Scale. Qual Life Res 2008;17:95-104.
13. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979;41: 209-218
14. Joseph S. Psychometric evaluation of Horowitz's Impact of Event Scale: a review. J Trauma Stress 2000;13:101-113
15. Brandberg Y, Månsson-Brahme E, Ringborg U, Sjödén PO. Psychological reactions in patients with malignant melanoma. Eur J Cancer 1995;31A:157-162
16. Michelson H, Bolund C, Nilsson B, Brandberg Y. Healthrelated Quality of Life measured by the EORTC QLQC30 - reference values from a large sample of the Swedish population. Acta Oncol 2000;39:477-484
17. Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol 2001;19: 2844-2850